Form 4: Cassava Sciences Director, Sanford Robertson, Acquires 15,000 Stock Options

Director Sanford Robertson acquired 15,000 stock options in Cassava Sciences Inc. on May 9, 2024, as part of the Non-employee Director Compensation Program.

Summary

• On May 9, 2024, Sanford Robertson, a director of Cassava Sciences Inc., acquired 15,000 stock options.
• The options were granted pursuant to the Non-employee Director Compensation Program approved by stockholders on May 4, 2023.
• The exercise price of the stock options is $21.11.
• The stock options vest over a one-year period at a rate of 1/12 per month.
• The expiration date for the options is May 9, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard director compensation practice, indicating alignment of interests between the director and shareholders. There are no red flags or negative implications apparent in the filing.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Industry Context

Director compensation packages often include stock options to incentivize performance and align director interests with shareholder value. This grant is part of a pre-approved program.

Comparison to Industry Standards

• Stock option grants are a common component of director compensation packages in the biotechnology industry.
• Companies like Biogen and Amgen also use stock options as part of their director compensation plans to align director interests with shareholder value.
• The vesting schedule of 1/12 per month over one year is a fairly standard vesting period for director stock options.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to decisions that increase shareholder value.

Key Dates